Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 198

1.

Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥ 2 mg/L). cmb@bcm.tmc.edu.

Ballantyne CM, Davidson MH, Setze CM, Kelly MT.

J Clin Lipidol. 2011 Sep-Oct;5(5):401-7. doi: 10.1016/j.jacl.2011.06.010.

PMID:
21981842
2.

One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.

Ferdinand KC, Davidson MH, Kelly MT, Setze CM.

Am J Cardiovasc Drugs. 2012 Apr 1;12(2):117-25. doi: 10.2165/11597940-000000000-00000.

PMID:
22263674
3.

Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.

Roth EM, Rosenson RS, Jones PH, Davidson MH, Kelly MT, Setze CM, Lele A, Thakker K.

J Clin Lipidol. 2012 Nov-Dec;6(6):534-44. doi: 10.1016/j.jacl.2012.02.002.

PMID:
23312049
4.

Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.

Jones PH, Davidson MH, Kashyap ML, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.

Atherosclerosis. 2009 May;204(1):208-15. doi: 10.1016/j.atherosclerosis.2008.09.027.

PMID:
18996523
5.

Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.

Roth EM, McKenney JM, Kelly MT, Setze CM, Carlson DM, Gold A, Stolzenbach JC, Williams LA, Jones PH.

Am J Cardiovasc Drugs. 2010;10(3):175-86. doi: 10.2165/11533430-000000000-00000.

PMID:
20524719
6.

The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.

Agouridis AP, Tsimihodimos V, Filippatos TD, Dimitriou AA, Tellis CC, Elisaf MS, Mikhailidis DP, Tselepis AD.

Expert Opin Pharmacother. 2011 Dec;12(17):2605-11. doi: 10.1517/14656566.2011.591383.

PMID:
21714585
7.

A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.

Weinstein DL, Williams LA, Carlson DM, Kelly MT, Burns KM, Setze CM, Lele A, Stolzenbach JC.

Clin Ther. 2013 Aug;35(8):1186-98. doi: 10.1016/j.clinthera.2013.06.013. Erratum in: Clin Ther. 2013 Nov;35(11):1862.

PMID:
23891363
8.

Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies.

Pepine CJ, Jacobson TA, Carlson DM, Kelly MT, Setze CM, Gold A, Stolzenbach JC, Williams LA.

Clin Cardiol. 2010 Oct;33(10):609-19. doi: 10.1002/clc.20830.

9.

Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.

Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, Sleep DJ, Stolzenbach JC.

Am J Cardiovasc Drugs. 2010;10(2):73-84. doi: 10.2165/10061630-000000000-00000.

PMID:
20136164
10.
11.

Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.

Roth EM, Rosenson RS, Carlson DM, Fukumoto SM, Setze CM, Blasetto JW, Khurmi NS, Stolzenbach JC, Williams LA.

Cardiovasc Drugs Ther. 2010 Dec;24(5-6):421-8. doi: 10.1007/s10557-010-6266-4.

PMID:
20953684
12.

Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.

Kipnes MS, Roth EM, Rhyne JM, Setze CM, Lele A, Kelly MT, Sleep DJ, Stolzenbach JC.

Clin Drug Investig. 2010;30(1):51-61. doi: 10.2165/11319800-000000000-00000.

PMID:
19995098
13.

Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.

Kei A, Liberopoulos E, Tellis K, Rizzo M, Elisaf M, Tselepis A.

Eur J Clin Invest. 2013 Jul;43(7):698-707. doi: 10.1111/eci.12095.

PMID:
23600368
14.

Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.

Ballantyne CM, Jones PH, Kelly MT, Setze CM, Lele A, Thakker KM, Stolzenbach JC.

Cardiovasc Drugs Ther. 2011 Feb;25(1):59-67. doi: 10.1007/s10557-011-6280-1.

15.

Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.

Rosenson RS, Carlson DM, Kelly MT, Setze CM, Hirshberg B, Stolzenbach JC, Williams LA.

Cardiovasc Drugs Ther. 2011 Feb;25(1):47-57. doi: 10.1007/s10557-010-6273-5.

16.

Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.

Jones PH, Bays HE, Davidson MH, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC.

Clin Drug Investig. 2008;28(10):625-34.

PMID:
18783301
17.

The high-dose rosuvastatin once weekly study (the HD-ROWS).

Backes JM, Gibson CA, Ruisinger JF, Moriarty PM.

J Clin Lipidol. 2012 Jul-Aug;6(4):362-7. doi: 10.1016/j.jacl.2011.11.002.

PMID:
22836073
18.
19.

Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.

Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, Tershakovec AM.

Curr Med Res Opin. 2006 Oct;22(10):2041-53.

PMID:
17022864
20.
Items per page

Supplemental Content

Support Center